Greenslade F C, Newquist K L
Arch Int Pharmacodyn Ther. 1978 Jun;233(2):270-80.
ORF 12592 caused concentration-dependent inhibition of isoproterenol stimulated adenylate cyclase activity in sarcolemma-enriched membrane preparations of guinea-pig myocardium. Its potency was slightly less than that of d,l-propranolol. ORF 12592 did not stimulate basal enzyme activity, suggesting it to be devoid of intrinsic sympathomimetic activity. It produced no marked inhibition of basal activity, nor did it inhibit sodium fluoride stimulated enzyme activity, indicating that the compound acts at the receptor rather than the catalytic site of the beta-adrenergic receptor-adenylate cyclase complex. ORF 12592 competed for binding of 3H-dihydroalprenolol to specific beta1 and beta2-adrenergic binding sites on turkey and leopard frog erythrocyte membranes respectively. Concentration-binding inhibition curves indicated that ORF 12592 is a non-selective beta-blocker with slightly less affinity for each beta-adrenergic receptor than propranolol.
ORF 12592对豚鼠心肌富含肌膜的膜制剂中异丙肾上腺素刺激的腺苷酸环化酶活性产生浓度依赖性抑制。其效力略低于d,l-普萘洛尔。ORF 12592不刺激基础酶活性,表明它没有内在拟交感活性。它对基础活性没有明显抑制作用,也不抑制氟化钠刺激的酶活性,这表明该化合物作用于β-肾上腺素能受体-腺苷酸环化酶复合物的受体而非催化位点。ORF 12592分别竞争3H-二氢阿普洛尔与火鸡和豹蛙红细胞膜上特定β1和β2肾上腺素能结合位点的结合。浓度-结合抑制曲线表明,ORF 12592是一种非选择性β受体阻滞剂,对每个β肾上腺素能受体的亲和力略低于普萘洛尔。